Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.67
BCR's Cash to Debt is ranked higher than
61% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BCR: 0.67 )
BCR' s 10-Year Cash to Debt Range
Min: 0.06   Max: 4.9
Current: 0.67

0.06
4.9
Equity to Asset 0.42
BCR's Equity to Asset is ranked higher than
57% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. BCR: 0.42 )
BCR' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.77
Current: 0.42

0.36
0.77
Interest Coverage 26.96
BCR's Interest Coverage is ranked higher than
70% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. BCR: 26.96 )
BCR' s 10-Year Interest Coverage Range
Min: 5   Max: 58.45
Current: 26.96

5
58.45
F-Score: 7
Z-Score: 4.21
M-Score: -2.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 39.79
BCR's Operating margin (%) is ranked higher than
98% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. BCR: 39.79 )
BCR' s 10-Year Operating margin (%) Range
Min: 13.55   Max: 39.79
Current: 39.79

13.55
39.79
Net-margin (%) 22.62
BCR's Net-margin (%) is ranked higher than
94% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. BCR: 22.62 )
BCR' s 10-Year Net-margin (%) Range
Min: 5.96   Max: 22.62
Current: 22.62

5.96
22.62
ROE (%) 33.03
BCR's ROE (%) is ranked higher than
98% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. BCR: 33.03 )
BCR' s 10-Year ROE (%) Range
Min: 12.62   Max: 44.45
Current: 33.03

12.62
44.45
ROA (%) 13.68
BCR's ROA (%) is ranked higher than
93% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BCR: 13.68 )
BCR' s 10-Year ROA (%) Range
Min: 5.65   Max: 23.37
Current: 13.68

5.65
23.37
ROC (Joel Greenblatt) (%) 146.51
BCR's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. BCR: 146.51 )
BCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 30.83   Max: 146.51
Current: 146.51

30.83
146.51
Revenue Growth (%) 9.50
BCR's Revenue Growth (%) is ranked higher than
80% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BCR: 9.50 )
BCR' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 13.9
Current: 9.5

-1.5
13.9
EBITDA Growth (%) 25.40
BCR's EBITDA Growth (%) is ranked higher than
91% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. BCR: 25.40 )
BCR' s 10-Year EBITDA Growth (%) Range
Min: -18.5   Max: 41
Current: 25.4

-18.5
41
EPS Growth (%) 16.70
BCR's EPS Growth (%) is ranked higher than
84% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. BCR: 16.70 )
BCR' s 10-Year EPS Growth (%) Range
Min: -14.8   Max: 43.2
Current: 16.7

-14.8
43.2
» BCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BCR Guru Trades in Q3 2013

RS Investment Management 34,610 sh (New)
Steven Cohen 19,506 sh (+43.88%)
Ray Dalio 28,486 sh (+24.47%)
Chuck Royce 61,330 sh (+12.78%)
Yacktman Fund 3,884,100 sh (unchged)
Yacktman Focused Fund 4,280,000 sh (unchged)
Sarah Ketterer Sold Out
Jeff Ubben Sold Out
Paul Tudor Jones Sold Out
Donald Yacktman 9,874,124 sh (-0.99%)
Pioneer Investments 989,137 sh (-1.4%)
Jeremy Grantham 116,498 sh (-11.57%)
Robert Olstein 41,000 sh (-14.58%)
Jim Simons 477,100 sh (-43.24%)
Joel Greenblatt 15,933 sh (-47.69%)
» More
Q4 2013

BCR Guru Trades in Q4 2013

Vanguard Health Care Fund 303,700 sh (New)
Paul Tudor Jones 2,600 sh (New)
Jim Simons 664,300 sh (+39.24%)
Pioneer Investments 990,073 sh (+0.09%)
Jeremy Grantham 105,513 sh (-9.43%)
Yacktman Fund 3,500,000 sh (-9.89%)
Chuck Royce 55,200 sh (-10%)
Joel Greenblatt 14,152 sh (-11.18%)
RS Investment Management 30,670 sh (-11.38%)
Robert Olstein 35,000 sh (-14.63%)
Steven Cohen 16,416 sh (-15.84%)
Donald Yacktman 7,755,464 sh (-21.46%)
Yacktman Focused Fund 3,000,000 sh (-29.91%)
Ray Dalio 19,786 sh (-30.54%)
» More
Q1 2014

BCR Guru Trades in Q1 2014

Vanguard Health Care Fund 1,839,200 sh (+505.6%)
Ray Dalio 43,186 sh (+118.27%)
Jeremy Grantham 199,094 sh (+88.69%)
Paul Tudor Jones 4,000 sh (+53.85%)
RS Investment Management 33,675 sh (+9.8%)
Chuck Royce Sold Out
Joel Greenblatt 13,984 sh (-1.19%)
Pioneer Investments 968,763 sh (-2.15%)
Yacktman Fund 3,424,600 sh (-2.15%)
Donald Yacktman 6,827,627 sh (-11.96%)
Robert Olstein 30,000 sh (-14.29%)
Yacktman Focused Fund 2,350,000 sh (-21.67%)
Jim Simons 463,600 sh (-30.21%)
Steven Cohen 2,314 sh (-85.9%)
» More
Q2 2014

BCR Guru Trades in Q2 2014

Yacktman Focused Fund 2,300,000 sh (-2.13%)
Yacktman Fund 3,330,000 sh (-2.76%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Yacktman Fund 2014-06-30 Reduce -2.76%0.12%$136.23 - $149.25 $ 145.832%3330000
Yacktman Focused Fund 2014-03-31 Reduce -21.67%0.91%$125.42 - $146.57 $ 145.836%2350000
Vanguard Health Care Fund 2014-03-31 Add 505.6%0.63%$125.42 - $146.57 $ 145.836%1839200
Donald Yacktman 2014-03-31 Reduce -11.96%0.51%$125.42 - $146.57 $ 145.836%6827627
Ray Dalio 2014-03-31 Add 118.27%0.03%$125.42 - $146.57 $ 145.836%43186
Yacktman Focused Fund 2013-12-31 Reduce -29.91%1.7%$113.84 - $139.85 $ 145.8310%3000000
Donald Yacktman 2013-12-31 Reduce -21.46%1.09%$113.84 - $139.85 $ 145.8310%7755464
Yacktman Fund 2013-12-31 Reduce -9.89%0.45%$113.84 - $139.85 $ 145.8310%3500000
Vanguard Health Care Fund 2013-12-31 New Buy0.13%$113.84 - $139.85 $ 145.8310%303700
Ray Dalio 2013-12-31 Reduce -30.54%0.01%$113.84 - $139.85 $ 145.8310%19786
Jeff Ubben 2013-09-30 Sold Out 0.85%$107.3 - $120.55 $ 145.8327%0
Joel Greenblatt 2013-09-30 Reduce -47.69%0.07%$107.3 - $120.55 $ 145.8327%15933
Ray Dalio 2013-09-30 Add 24.47%0.01%$107.3 - $120.55 $ 145.8327%28486
Jeff Ubben 2013-06-30 Reduce -79.02%3.24%$98.25 - $111.8 $ 145.8340%758704
Yacktman Focused Fund 2013-06-30 Add 27.8%1.26%$98.25 - $111.8 $ 145.8340%4280000
Yacktman Fund 2013-06-30 Add 29.9%1.06%$98.25 - $111.8 $ 145.8340%3884100
Donald Yacktman 2013-06-30 Add 24.46%1%$98.25 - $111.8 $ 145.8340%9973185
Ray Dalio 2013-06-30 Reduce -65.99%0.04%$98.25 - $111.8 $ 145.8340%22886
Joel Greenblatt 2013-06-30 Add 25.09%0.03%$98.25 - $111.8 $ 145.8340%30459
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CR Bard Inc

Yacktman Funds Comments on C.R. Bard Inc. - Mar 12, 2014

During the fourth quarter, C.R. Bard Inc’s shares rose sharply as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years.



From Yacktman Funds' 2013 Annual Report - Portfolio Manager's Comments



Check out Donald Yacktman latest stock trades

Yacktman Fund Comments on C.R. Bard Inc. - Jan 30, 2014

C.R. Bard Inc. (BCR)'s shares rose sharply during the quarter as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years.

From the Yacktman Fund (Trades, Portfolio)s' fourth quarter 2013 shareholder update.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about CR Bard Inc

Yacktman Funds Comments on C.R. Bard Inc.
During the fourth quarter, C.R. Bard Inc’s shares rose sharply as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years. Read more...
Yacktman Fund Comments on C.R. Bard Inc.
C.R. Bard Inc. (BCR)'s shares rose sharply during the quarter as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years. Read more...
Weekly Insider Sells Highlight: BCR, GLUU, AMT, APOL, JACK
According to GuruFocus Insider Data, the largest insider sells during the past week were: C.R. Bard Inc., Glu Mobile Inc., American Tower Corp., Apollo Education Group Inc. and Jack in the Box Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 15.50
BCR's P/E(ttm) is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.10 vs. BCR: 15.50 )
BCR' s 10-Year P/E(ttm) Range
Min: 14.48   Max: 80.1
Current: 15.5

14.48
80.1
P/B 5.50
BCR's P/B is ranked higher than
58% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. BCR: 5.50 )
BCR' s 10-Year P/B Range
Min: 3.22   Max: 7.24
Current: 5.5

3.22
7.24
P/S 3.80
BCR's P/S is ranked higher than
66% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. BCR: 3.80 )
BCR' s 10-Year P/S Range
Min: 2.55   Max: 4.66
Current: 3.8

2.55
4.66
PFCF 11.70
BCR's PFCF is ranked higher than
97% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 81.48 vs. BCR: 11.70 )
BCR' s 10-Year PFCF Range
Min: 10.12   Max: 47.48
Current: 11.7

10.12
47.48
EV-to-EBIT 7.24
BCR's EV-to-EBIT is ranked higher than
96% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. BCR: 7.24 )
BCR' s 10-Year EV-to-EBIT Range
Min: 7   Max: 20
Current: 7.24

7
20
PEG 0.80
BCR's PEG is ranked higher than
97% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. BCR: 0.80 )
BCR' s 10-Year PEG Range
Min: 0.8   Max: 33.97
Current: 0.8

0.8
33.97
Shiller P/E 25.00
BCR's Shiller P/E is ranked higher than
92% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 25.00 )
BCR' s 10-Year Shiller P/E Range
Min: 19.61   Max: 42.12
Current: 25

19.61
42.12
Current Ratio 3.65
BCR's Current Ratio is ranked higher than
84% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. BCR: 3.65 )
BCR' s 10-Year Current Ratio Range
Min: 1.14   Max: 5.88
Current: 3.65

1.14
5.88
Quick Ratio 2.97
BCR's Quick Ratio is ranked higher than
84% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. BCR: 2.97 )
BCR' s 10-Year Quick Ratio Range
Min: 0.62   Max: 4.72
Current: 2.97

0.62
4.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.60
BCR's Dividend Yield is ranked lower than
78% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. BCR: 0.60 )
BCR' s 10-Year Dividend Yield Range
Min: 0.56   Max: 1.31
Current: 0.6

0.56
1.31
Dividend Payout 0.09
BCR's Dividend Payout is ranked higher than
98% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 0.09 )
BCR' s 10-Year Dividend Payout Range
Min: 0.03   Max: 1.32
Current: 0.09

0.03
1.32
Dividend growth (3y) 5.40
BCR's Dividend growth (3y) is ranked higher than
74% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. BCR: 5.40 )
BCR' s 10-Year Dividend growth (3y) Range
Min: 3.2   Max: 7.4
Current: 5.4

3.2
7.4
Yield on cost (5-Year) 0.79
BCR's Yield on cost (5-Year) is ranked lower than
68% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.47 vs. BCR: 0.79 )
BCR' s 10-Year Yield on cost (5-Year) Range
Min: 0.74   Max: 1.72
Current: 0.79

0.74
1.72
Share Buyback Rate 5.20
BCR's Share Buyback Rate is ranked higher than
96% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BCR: 5.20 )
BCR' s 10-Year Share Buyback Rate Range
Min: 5.2   Max: -1.5
Current: 5.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
BCR's Price/DCF (Projected) is ranked higher than
90% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.59 vs. BCR: 1.30 )
BCR' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 2.26
Current: 1.3

0.89
2.26
Price/Median PS Value 1.10
BCR's Price/Median PS Value is ranked higher than
75% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. BCR: 1.10 )
BCR' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 1.3
Current: 1.1

0.38
1.3
Price/Peter Lynch Fair Value 1.70
BCR's Price/Peter Lynch Fair Value is ranked higher than
94% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BCR: 1.70 )
BCR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 8.39
Current: 1.7

0.4
8.39
Earnings Yield (Greenblatt) 13.80
BCR's Earnings Yield (Greenblatt) is ranked higher than
91% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. BCR: 13.80 )
BCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5   Max: 14.3
Current: 13.8

5
14.3
Forward Rate of Return (Yacktman) 12.58
BCR's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 257 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. BCR: 12.58 )
BCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.1   Max: 23.3
Current: 12.58

-5.1
23.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BR6.Germany
C.R. Bard, Inc., was incorporated in 1923. The Company engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The company participates in the markets for vascular, urology, oncology and surgical specialty products. The company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialties. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease ('PVD') and heart arrhythmias. These products include: percutaneous transluminal angioplasty ('PTA') catheters, chronic total occlusion ('CTO') catheters, guidewires, fabrics, meshes, introducers and accessories; peripheral vascular stents, covered stents and vascular grafts; vena cava filters; biopsy devices; and electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters. The Company's urology products include basic drainage products, continence products and urological specialty products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. The company's soft tissue repair products consist of hernia repair grafts, including both synthetic and natural-tissue configurations, and hernia fixation devices. The Company competes in the therapeutic and diagnostic medical device markets around the world. The Company's products are distributed domestically directly to hospitals and other healthcare institutions as well as through numerous hospitals/surgical supply and other medical specialty distributors with whom the Company has distribution agreements. The company is subject to various environmental laws and regulations both within and outside the United States.
» More Articles for BCR

Headlines

Articles On GuruFocus.com
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Yacktman Funds Comments on C.R. Bard Inc. Mar 12 2014 
Yacktman Fund Comments on C.R. Bard Inc. Jan 30 2014 
Yacktman Focused Fund & Yacktman Fund Fourth Quarter Commentary Jan 30 2014 
Weekly Insider Sells Highlight: BCR, GLUU, AMT, APOL, JACK Jan 20 2014 
Yacktman Fund Buys Oracle, Exxon Mobil, C.R. Bard, Sells Pfizer, Viacom, Microsoft Jul 17 2013 
The Yacktman Fund's Top 5 Second Quarter Increases Jul 16 2013 
My 3 Favorite Stocks with Recent Dividend Growth Jun 16 2013 
Covidien – Positive Results for Life Jun 09 2013 

More From Our Partners
Earnings Scheduled For July 24, 2014 Jul 24 2014 - BENZINGA

More From Other Websites
C R Bard Inc Earnings Call scheduled for 5:00 pm ET today Jul 24 2014
BARD C R INC /NJ/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 24 2014
Bard Announces Second Quarter Results Jul 24 2014
Q2 2014 C. R. Bard, Inc. Earnings Release - After Market Close Jul 24 2014
Why Lower-Yielding Stocks Provide Better Long-Term Returns Jul 10 2014
Bard to Host Earnings Conference Call on July 24, 2014 Jul 01 2014
3 Stocks Pulling The Health Services Industry Downward Jun 30 2014
C.R. Bard downgraded by Barclays Jun 18 2014
Headwinds For C.R. Bard, According To Barclays Jun 18 2014
Will This Analyst Downgrade Hurt C.R. Bard (BCR) Stock Today? Jun 18 2014
'Fast Money' Recap: Opening the Oil Spigot? Jun 17 2014
CR Bard Expands Share Repurchase Program Jun 16 2014
CR Bard's Lutonix DCB Moves Closer to FDA Clearance Jun 13 2014
FDA Advisory Panel Supports Novel Drug Coated Balloon Jun 13 2014
Circulatory System Devices Advisory Panel Provides a Unanimous Favorable Recommendation to FDA for... Jun 12 2014
Bard Announces $500 Million Share Repurchase Authorization Jun 11 2014
Bard Increases Quarterly Dividend Jun 11 2014
3 Stocks Pushing The Health Care Sector Lower Jun 11 2014
CR Bard (BCR) Shows Signs Of Being Water-Logged And Getting Wetter Jun 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide